INSPIRE: Raltegravir (Isentress) Pilot Study in Relapsing MS

Registry ID

EUCTR2012-004847-61

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

Queen Mary University of London

Start date

2013-01-16

Completion date

2015-06-10

Last update

2026-08-16

Conditions

• Relapsing Remitting Multiple Sclerosis

Summary

The primary objective is to assess whether treatment with raltegravir in patients with active MS has the effect of reducing the total number or rate of development of new or recurrent Gd-enhanced lesions on brain MRI over the period of treatment, compared to baseline.

Locations

• , , UK

Related clinical trials

• A Phase 3, Multicenter, Double Blind, Active-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Ozanimod Compared to Oral Fingolimod in Children and Adolescents with Relapsing Remitting Multiple Sclerosis
• The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study
• Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
• SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis
• Visual Processing Speed and Objective Analysis of Ocular Movements in Multiple Sclerosis
• Rituximab and Ocrelizumab in Serum With Multiple Sclerosis

View on source registry